The influence of proteasome inhibitor on the expression of cardiomyocytes damage markers after incubation with doxorubicin

1. Adams J.: Development of the Proteasome Inhibitor PS-341. The Oncologist, 7, 9, 2002.10.1634/theoncologist.7-1-911854543Search in Google Scholar

2. Aihara Y. et al.: Doxorubicin Represses CARP Gene Transcription Through the Generation of Oxidative Stress in Neonatal Rat Cardiac Myocytes: Possible Role of Serine/Threonine Kinase - dependent Pathways. J. Mol. Cell Cardiol., 32, 1401, 2000.10.1006/jmcc.2000.117310900167Search in Google Scholar

3. Batheja R. et al.: Paradoxical decrease in plasma N-terminal-proBNP (NTproBNP) levels in patients receiving doxorubicin chemotherapy and declining left ventricular ejection fraction. J. Am. Coll. Cardiol., 47, 66A, 2006.Search in Google Scholar

4. Chen S., Garami M., Gardner D. G.: Doxorubicin Selectively Inhibits Brain Versus Atrial Natriuretic Peptide Gene Expression in Cultured Neonatal Rat Myocytes. Hypertension, 34, 1223, 1999.Search in Google Scholar

5. Dudka J.: The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity. Postepy Hig. Med. Dosw, 60, 241, 2006.Search in Google Scholar

6. Dudka J. et al.: The diagnosis of anthracycline-induced cardiac damage and heart failure. Postepy Hig. Med. Dosw , 63, 225, 2009.Search in Google Scholar

7. Hacihanefioglu A., Tarkun P., GonulluE.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol., 88, 219, 2008.Search in Google Scholar

8. Hedhli N., Depre Ch.: Proteasome inhibitors and cardiac cell growth. Cardiovasc. Res., 85, 321, 2010.Search in Google Scholar

9. Korga A. et al.: The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin. Oxid. Med. Cell Longev., 681367, 2012.10.1155/2012/681367331706122530076Search in Google Scholar

10. Liu J. et al.: A therapeutic dose of doxorubicin activates ubiquitinproteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am. J. Physiol. Heart Circ. Physiol., 295, H2541, 2008.10.1152/ajpheart.01052.2008265402818978187Search in Google Scholar

11. Lyu Y. L. et al.: TopoisomeraseIIb-Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxity and Prevention by Dexrazoxane. Cancer Res., 67, 8839, 2007.10.1158/0008-5472.CAN-07-164917875725Search in Google Scholar

12. Minotti G. et al.: Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxity. Pharmacol. Rev., 56, 185, 2004.10.1124/pr.56.2.615169927Search in Google Scholar

13. Pichon M. F. et al.: Drug - induced Cardiotoxity Studied by Longitudinal B-Type Natriuretic Peptide Asays and Radionuclide Ventryculography. In Vivo, 19, 567, 2005.Search in Google Scholar

14. Ranek M. J., Wang X.: Activation of the Ubiquitin Proteasome System in Doxorubicin Cardiomyopathy. Curr. Hypertens. Rep., 11, 389, 2009.Search in Google Scholar

15. Sayed-Ahmad M. M. et al.: Protection by L-Carnitine Against the Inhibition of Gene Expression of Heart Fatty Acid Binding Protein by Chronic Administration of Doxorubicin. Journal of the Egyptian Nat. Cancer Inst., 4, 275, 2000.Search in Google Scholar

16. Sayed-Ahmed M. M. et al.: Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur. J. Pharmacol., 640, 143, 2010.10.1016/j.ejphar.2010.05.00220470772Search in Google Scholar

17. Sun Y. et al.: B-Type Natriuretic Peptide-Induced Cardioprotection against Reperfusion Is Associated with Attenaution of Mitochondrial Permeability Transition. Biol. Pharm. Bull, 32, 1545, 2009.10.1248/bpb.32.154519721230Search in Google Scholar

18. Szuławska A., Czyż M.: Molecular mechanisms of anthracyclines action. Postepy Hig. Med. Dosw., 60, 78, 2006.Search in Google Scholar

19. Tsutsui H., Kinugawa S., Matsushima S.: Oxidative Stress and Mitochondrial DNA Damage in Heart Failure”,Circ. J., Suppl Am, A-31, 2008.10.1253/circj.CJ-08-0014Search in Google Scholar

20. Voortman J., GiacconeG.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer, 6, 129, 2006.Search in Google Scholar